REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
Jan 31, 2020
Oxford, UK – Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat cancer and chronic infectious diseases, announces top line Phase 2 data and plans for its recombinant Modified Vaccinia Ankara (MVA) Universal Influenza A prophylactic vaccine, VTP-100, clinically developed to address both pandemic and seasonal influenza.
A Data Monitoring Committee (DMC) performed an unblinded analysis of interim results from FLU009, a single-blind, randomised, placebo-controlled field Phase 2b trial for seasonal influenza with 2,149 participants, sponsored in Australia by Vaccitech’s wholly-owned subsidiary, Vaccitech Australia Pty Limited. The DMC recommendation is that the trial should not be continued for a second season. The committee’s analysis indicates that while the vaccine was safe and well tolerated, the trial is unlikely to meet the primary endpoint and achieve the required level of reduction in the incidence of laboratory-confirmed influenza in participants receiving VTP-100 as an add-on to a licenced seasonal Quadrivalent Influenza Vaccine (QIV), relative to participants receiving QIV alone.
In addition, data from FLU010, a randomised, double-blind, placebo-controlled, influenza challenge Phase 2 trial for pandemic influenza in 118 healthy adults did not reach its primary endpoint of a thirty percent reduction in overall viral shedding. Vaccitech will continue its obligations under the contract with BARDA to analyse potential immunological correlates associated with protection or risk from disease. The trial was conducted under review by both the FDA and the Belgian Regulatory Authority, FAMHP.
RR, Thank you for that reminder. I can understand why people I forwarded it too are excited by the prospect that MUCH has already been done.
For the vast majority who are not vulnerable, even if it means repeat injections when their antibodies die out. Still looking to understand more.
Morning Ruck
It is interesting that Sarah Gilbert was involved in the universal flu vaccine. This produces
T Cells that target a core protein rather than producing antibodies.
https://en.m.wikipedia.org/wiki/Sarah_Gilbert
I thought it was a good program, documenting what has actually happened and what is actually happening. We shouldn’t judge it by what we think SHOULD be happening.
Looks like Prof Sarah Gilbert is the Lindy Durrant of the virology world.
I would have thought that the best combination of T Cells plus neutralizing antibodies thrown in for good measure would stand a chance.
I saw the bit about combinations, it sounded a bit like 'throw the kitchen sink at it and see what happens.' Not exactly reassuring.
I'm sure it will be on All4 too.. And plan to seek it out this am. People who don't know as much as those of us who catch up here when we can, have been very positive.
To me, it opens a dialogue to help them back funding for other projects.
I don't actually have much hope for the vaccine trials underway as I read that Germany's patient ZERO has no antibodies at all left. I asked if they tested for memory T-cells, but the journo didn't say. I think the person supplying the info would have said something if they had been present.
Maybe the only interesting part was when they started taliking about combinations..................at this stage!!!
Hardly gave me any confidence in the lead trials already underway.
Agree just watched Ch4 ... its was more like a revision of the news from the last six months rather than a Documentary focusing on the development of vaccines, they could have looked at all the different platforms DNA, RNA, Viral, etc ... so not impressed and has no value added content for this BB.
Agree, I fell asleep twice lol.
Good Morning Guys,/Gals
I was rather underwhelmed by that documentary last night, or was it the vaccines under scrutiny are pretty underwhelming themselves, or was it me that felt pretty tired watching it. Anyone got any thought as to it??
Although it's started you can watch it on your channel 4+1 channel at 10pm